A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer.

Trial Profile

A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2014 Completion date is 1 May 2012 as reported by ClinicalTrials.gov.
    • 13 Jan 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 31 May 2013 Planned end date changed from 1 Jun 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top